Literature DB >> 29061737

Antifungal Activity of Oleylphosphocholine on In Vitro and In Vivo Candida albicans Biofilms.

Michelle Holtappels1,2, Erwin Swinnen1,2,3, Lies De Groef4, Jurgen Wuyts1,2, Lieve Moons4, Katrien Lagrou5, Patrick Van Dijck6,2, Soňa Kucharíková1,2.   

Abstract

In this study, we investigated the potential antifungal activity of the alkylphospholipid oleylphosphocholine (OlPC), a structural analogue of miltefosine, on in vitro and in vivoCandida albicans biofilm formation. The effect of OlPC on in vitro and in vivoC. albicans biofilms inside triple-lumen polyurethane catheters was studied. In vivo biofilms were developed subcutaneously after catheter implantation on the lower back of Sprague-Dawley rats. Animals were treated orally with OlPC (20 mg/kg of body weight/day) for 7 days. The effect of OlPC on biofilms that developed on the mucosal surface was studied in an ex vivo model of oral candidiasis. The role of OlPC in C. albicans morphogenesis was investigated by using hypha-inducing media, namely, Lee, Spider, and RPMI 1640 media. OlPC displayed activity against both planktonic cells and in vitroC. albicans biofilms. To completely abolish preformed, 24-h-old biofilms, higher concentrations (8, 10, and 13 mg/liter) were needed. Moreover, OlPC was able to reduce C. albicans biofilms formed by caspofungin-resistant clinical isolates and acted synergistically when combined with caspofungin. The daily oral administration of OlPC significantly reduced in vivoC. albicans biofilms that developed subcutaneously. In addition, OlPC decreased biofilm formation on mucosal surfaces. Interestingly, the application of subinhibitory concentrations of OlPC already inhibited the yeast-to-hypha transition, a crucial virulence factor of C. albicans We document, for the first time, the effects of OlPC on C. albicans cells and suggest the potential use of OlPC for the treatment of C. albicans biofilm-associated infections.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Candida albicans; OlPC; caspofungin; in vitro biofilm; in vivo biofilm; oleylphosphocholine

Mesh:

Substances:

Year:  2017        PMID: 29061737      PMCID: PMC5740347          DOI: 10.1128/AAC.01767-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

Review 1.  Candida Biofilms: Development, Architecture, and Resistance.

Authors:  Jyotsna Chandra; Pranab K Mukherjee
Journal:  Microbiol Spectr       Date:  2015-08

Review 2.  Pathogenesis of Candida albicans biofilm.

Authors:  Christina Tsui; Eric F Kong; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2016-06       Impact factor: 3.166

Review 3.  Oral candidosis--clinical challenges of a biofilm disease.

Authors:  Riina Rautemaa; Gordon Ramage
Journal:  Crit Rev Microbiol       Date:  2011-07-21       Impact factor: 7.624

4.  An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida Albicans.

Authors:  K L Lee; H R Buckley; C C Campbell
Journal:  Sabouraudia       Date:  1975-07

5.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

6.  Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog.

Authors:  H Liu; J Köhler; G R Fink
Journal:  Science       Date:  1994-12-09       Impact factor: 47.728

7.  Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model.

Authors:  Sona Kucharíková; Nidhi Sharma; Isabel Spriet; Johan Maertens; Patrick Van Dijck; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

8.  Mitochondrial Activity and Cyr1 Are Key Regulators of Ras1 Activation of C. albicans Virulence Pathways.

Authors:  Nora Grahl; Elora G Demers; Allia K Lindsay; Colleen E Harty; Sven D Willger; Amy E Piispanen; Deborah A Hogan
Journal:  PLoS Pathog       Date:  2015-08-28       Impact factor: 6.823

9.  Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management.

Authors:  Shyam Sundar; Piero L Olliaro
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

10.  Oleylphosphocholine (OlPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice.

Authors:  Karine Sonzogni-Desautels; Axel E Renteria; Fabio V Camargo; Thomas Z Di Lenardo; Alexandre Mikhail; Michael J Arrowood; Anny Fortin; Momar Ndao
Journal:  Front Microbiol       Date:  2015-09-23       Impact factor: 5.640

View more
  2 in total

Review 1.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

Review 2.  Bioactive Peptides Against Fungal Biofilms.

Authors:  Karen G N Oshiro; Gisele Rodrigues; Bruna Estéfani D Monges; Marlon Henrique Cardoso; Octávio Luiz Franco
Journal:  Front Microbiol       Date:  2019-10-04       Impact factor: 5.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.